semaglutide heat intolerance does cause Several medications can lose potency in extreme heat, rendering them ineffective Some Drugs Can Make You

Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide

doi:10.3390/ijms23084334 23

Avoid alcohol, as it may increase drowsiness and dizziness

Greco V, Bergamo D, Cuoccio P, Konkoly KR, Munoz Lombardo K, Lewis PA